Physician profile
Meaghan M Canton-Feder
NPI 1144401571
$3,032.65
in general payments reported to CMS, 2019-2025
21 companies · $644 in 2025
The $644 reported for 2025 was more than what 97% of Licensed Practical Nurse providers received nationally (typical 2025 total: $38.94).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2.84 · 2022: $331 · 2023: $1,206 · 2024: $849 · 2025: $644.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,484 · Education: $214.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,484.33 |
| Education | $214.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $734.74 | 2022-2024 | Tremfya |
| Incyte Corporation | $448.85 | 2022-2025 | Opzelura |
| Sun Pharmaceutical Industries INC. | $338.71 | 2022-2025 | Absorica Ld, Winlevi, Blu-U |
| Genzyme Corporation | $287.47 | 2022-2025 | |
| Abbvie INC. | $197.89 | 2022-2025 | |
| Arcutis Biotherapeutics, INC. | $146.99 | 2023-2025 | Zoryve |
| Revance Therapeutics, INC. | $123.26 | 2024-2025 | Daxxify |
| Journey Medical Corporation | $107.01 | 2022-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $106.31 | 2023-2025 | Jublia, Cabtreo, Arazlo |
| Pfizer INC. | $103.00 | 2022-2023 | |
| Biofrontera INC. | $95.06 | 2023-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Lilly USA, LLC | $91.17 | 2022-2025 | Taltz, Ebglyss, Olumiant |
| E.R. Squibb & Sons, L.L.C. | $53.02 | 2022-2024 | Sotyktu |
| Amgen INC. | $51.25 | 2023-2025 | Otezla, Otezla |
| Regeneron Healthcare Solutions, INC. | $36.39 | 2024 | Dupixent |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $30.13 | 2025 | Vtama |
| Kyowa Kirin, INC. | $25.51 | 2022 | |
| Novartis Pharmaceuticals Corporation | $20.64 | 2025 | |
| Dermavant Sciences, INC. | $17.04 | 2024 | Vtama |
| Galderma Laboratories, L.P. | $15.37 | 2025 | Aklief |
| Quidel Corporation | $2.84 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Meaghan Canton-Feder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.